CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
Recruiting now · Phase 1/Phase 2
Conditions studied: T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL)
In brief
This is a multi-center, open-label, non-randomized, single-arm clinical trial. Refractory/relapse T-NHL patients are treated with autologous and allogeneic CD7 CAR T-cell therapy. The primary objective is to prospectively evaluate the safety of CD7 CAR T cell bridging to HSCT in the treatment of r/r T-NHL. The primary endpoint is the type and incidence of dose limiting toxicity (DLT) within 21 days after CD7 CAR-T cell infusion. A total of 36 subjects is estimated to be enrolled.
Key facts
- Study ID
- NCT06925464
- Run by
- Beijing GoBroad Hospital
- People needed
- 36
- Starts
- 2025-04-01
- Expected to finish
- 2027-04-01
- Last updated by the study team
- 2025-05-13
Who can join
Age: 14 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Beijing GoBroad Hospital — Beijing, Beijing Municipality, China (enrolling)
- 湛江中心人民医院 — Zhanjiang, Guangdong, China (enrolling)
- Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine — Shanghai, Shanghai Municipality, China (enrolling)
- Shanghai Liquan Hospital — Shanghai, Shanghai Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.